{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:11:46Z","timestamp":1787065906988,"version":"build-2736575974"},"posted":{"date-parts":[[2025,11,3]]},"group-title":"In Review","reference-count":74,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,3]]},"abstract":"<title>Abstract<\/title>\n                <p>Understanding how antigenic distance influences cross-reactive responses can inform vaccine design. Multivalent displays of viral proteins can improve B cell activation due to receptor cross-linking, and mosaic nanoparticles that incorporate variants can lead to cross-reactive B cell responses recognizing conserved epitopes. Here, we used the influenza virus neuraminidase to develop a neuraminidase-on-a-string platform displaying neuraminidase dimer pairs conjugated to a nanocarrier To systematically assess the influence of antigenic distance on humoral immunity, we paired H2N2 neuraminidase with either divergent H3N2 or H11N9 neuraminidases. We found that nanoparticle immunizations with heterologous antigens elicited sera with greater breadth and enhanced enzymatic inhibition relative to immunizations that incorporated a single neuraminidase strain. While sera reactivity for H2N2 neuraminidase was not impacted by inclusion of a second strain, strain-specific responses correlatively increased with the antigenic distance between neuraminidase components. These data show how neuraminidase strain selection for multivalent display immunizations influences elicited breadth and cross-reactivity, highlighting findings that may extend to other viral antigens.<\/p>","DOI":"10.21203\/rs.3.rs-7530142\/v1","type":"posted-content","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T18:22:51Z","timestamp":1762194171000},"source":"Crossref","is-referenced-by-count":1,"title":["Neuraminidase-on-a-string nanoparticles probe how antigenic distance shapes elicited humoral immunity"],"prefix":"10.21203","author":[{"given":"Rochel","family":"Hecht","sequence":"first","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faez Amokrane Nait","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lingwood","sequence":"additional","affiliation":[{"name":"Ragon Institute of MGH, MIT and Harvard"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"107413","DOI":"10.1016\/j.bpc.2025.107413","article-title":"SARS-CoV-2 variants: Mutations, viral stability, and breakthroughs in vaccines and therapies","volume":"320\u2013321","author":"Abduljaleel Z","year":"2025","unstructured":"Abduljaleel, Z. Decoding SARS-CoV-2 variants: Mutations, viral stability, and breakthroughs in vaccines and therapies. Biophys. Chem. 320\u2013321, 107413 (2025).","journal-title":"Biophys. Chem."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.immuni.2025.02.006","article-title":"Antigenic drift expands influenza viral escape pathways from recalled humoral immunity","volume":"58","author":"Maurer DP","year":"2025","unstructured":"Maurer, D. P., Vu, M. & Schmidt, A. G. Antigenic drift expands influenza viral escape pathways from recalled humoral immunity. Immunity 58, 716\u2013727.e6 (2025).","journal-title":"Immunity"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.immuni.2018.12.017","article-title":"An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes","volume":"50","author":"Dingens AS","year":"2019","unstructured":"Dingens, A. S., Arenz, D., Weight, H., Overbaugh, J. & Bloom, J. D. An Antigenic Atlas of HIV-1 Escape from Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes. Immunity 50, 520\u2013532.e3 (2019).","journal-title":"Immunity"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev-immunol-072621-084422","article-title":"Evolutionary Landscapes of Host-Virus Arms Races","volume":"40","author":"Tenthorey JL","year":"2022","unstructured":"Tenthorey, J. L., Emerman, M. & Malik, H. S. Evolutionary Landscapes of Host-Virus Arms Races. Annu. Rev. Immunol. 40, 271\u2013294 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00417-1","article-title":"Protein engineering strategies for rational immunogen design","volume":"6","author":"Caradonna TM","year":"2021","unstructured":"Caradonna, T. M. & Schmidt, A. G. Protein engineering strategies for rational immunogen design. Npj Vaccines 6, (2021).","journal-title":"Npj Vaccines"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine HM","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065\u20131070 (2015).","journal-title":"Nat. Med."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2018.07.005","article-title":"Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies","volume":"49","author":"Duan H","year":"2018","unstructured":"Duan, H. et al. Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. Immunity 49, 301\u2013311 (2018).","journal-title":"Immunity"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.737973","article-title":"Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization","volume":"12","author":"Thornlow DN","year":"2021","unstructured":"Thornlow, D. N. et al. Altering the Immunogenicity of Hemagglutinin Immunogens by Hyperglycosylation and Disulfide Stabilization. Front. Immunol. 12, (2021).","journal-title":"Front. Immunol."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.chom.2019.04.003","article-title":"Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope","volume":"25","author":"Bajic G","year":"2019","unstructured":"Bajic, G. et al. Influenza Antigen Engineering Focuses Immune Responses to a Subdominant but Broadly Protective Viral Epitope. Cell Host Microbe 25, 827\u2013835.e6 (2019).","journal-title":"Cell Host Microbe"},{"key":"ref10","author":"Caradonna TM","unstructured":"Caradonna, T. M. et al. An Epitope-Enriched Immunogen Expands Responses to a Conserved Viral Site 1 2 3 4 Authors."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006271","article-title":"Complete mapping of viral escape from neutralizing antibodies","author":"Doud MB","year":"2017","unstructured":"Doud, M. B., Hensley, S. E. & Bloom, J. D. Complete mapping of viral escape from neutralizing antibodies. PLOS Pathog. (2017) doi:10.1371\/journal.ppat.1006271.","journal-title":"PLOS Pathog"},{"key":"ref12","author":"Lamson DT","year":"2025","unstructured":"Lamson, D. T. et al. A modular platform to display multiple hemagglutinin subtypes on a single immunogen. eLife 13, (2025)."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo CP","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3390\/vaccines12070714","article-title":"Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern","volume":"12","author":"Kumari M","year":"2024","unstructured":"Kumari, M. et al. Multivalent mRNA Vaccine Elicits Broad Protection against SARS-CoV-2 Variants of Concern. Vaccines 12, 714 (2024).","journal-title":"Vaccines"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41565-020-0719-0","article-title":"Role of nanoscale antigen organization on B-cell activation probed using DNA origami","volume":"15","author":"Veneziano R","year":"2020","unstructured":"Veneziano, R. et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat. Nanotechnol. 15, 716\u2013723 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00956","article-title":"Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses","volume":"10","author":"Slifka MK","year":"2019","unstructured":"Slifka, M. K. & Amanna, I. J. Role of Multivalency and Antigenic Threshold in Generating Protective Antibody Responses. Front. Immunol. 10, (2019).","journal-title":"Front. Immunol."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14760584.2019.1578216","article-title":"Immunological basis for enhanced immunity of nanoparticle vaccines","volume":"18","author":"Kelly HG","year":"2019","unstructured":"Kelly, H. G., Kent,Stephen J & and Wheatley, A. K. Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Rev. Vaccines 18, 269\u2013280 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"18848","DOI":"10.1038\/srep18848","article-title":"Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology","volume":"6","author":"Li Y","year":"2016","unstructured":"Li, Y. et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Sci. Rep. 6, 18848 (2016).","journal-title":"Sci. Rep."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3390\/ijms20133158","article-title":"Immunization of Rabbits with Recombinant Human Cytomegalovirus Trimeric versus Monomeric gH\/gL Protein Elicits Markedly Higher Titers of Antibody and Neutralization Activity","volume":"20","author":"Cui X","year":"2019","unstructured":"Cui, X. et al. Immunization of Rabbits with Recombinant Human Cytomegalovirus Trimeric versus Monomeric gH\/gL Protein Elicits Markedly Higher Titers of Antibody and Neutralization Activity. Int. J. Mol. Sci. 20, 3158 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2004119","DOI":"10.1002\/adfm.202004119","article-title":"Leveraging the modularity of biomaterial carriers to tune immune responses","volume":"30","author":"Tsai SJ","year":"2020","unstructured":"Tsai, S. J., Black, S. K. & Jewell, C. M. Leveraging the modularity of biomaterial carriers to tune immune responses. Adv. Funct. Mater. 30, 2004119 (2020).","journal-title":"Adv. Funct. Mater."},{"key":"ref21","article-title":"Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles","volume":"6","author":"Brouwer PJM","year":"2021","unstructured":"Brouwer, P. J. M. et al. Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles. Npj Vaccines 6, (2021).","journal-title":"Npj Vaccines"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.immuni.2023.08.011","article-title":"Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses","volume":"56","author":"Ols S","year":"2023","unstructured":"Ols, S. et al. Multivalent antigen display on nanoparticle immunogens increases B cell clonotype diversity and neutralization breadth to pneumoviruses. Immunity 56, 2425\u20132441.e14 (2023).","journal-title":"Immunity"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","article-title":"Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo","volume":"53","author":"Kato Y","year":"2020","unstructured":"Kato, Y. et al. Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo. Immunity 53, 548\u2013563.e8 (2020).","journal-title":"Immunity"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"110003","DOI":"10.1016\/j.vetmic.2024.110003","article-title":"Enhancing humoral and mucosal immune response of PED vaccine candidate by fusing S1 protein to nanoparticle multimerization","volume":"290","author":"Li M","year":"2024","unstructured":"Li, M. et al. Enhancing humoral and mucosal immune response of PED vaccine candidate by fusing S1 protein to nanoparticle multimerization. Vet. Microbiol. 290, 110003 (2024).","journal-title":"Vet. Microbiol."},{"key":"ref25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","article-title":"Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens","volume":"48","author":"Abbott RK","year":"2018","unstructured":"Abbott, R. K. et al. Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. Immunity 48, 133\u2013146.e6 (2018).","journal-title":"Immunity"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen MO","year":"2022","unstructured":"Mohsen, M. O. & Bachmann, M. F. Virus-like particle vaccinology, from bench to bedside. Cell. Mol. Immunol. 19, 993\u20131011 (2022).","journal-title":"Cell. Mol. Immunol."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature13404","article-title":"Accurate design of co-assembling multi-component protein nanomaterials","volume":"510","author":"King NP","year":"2014","unstructured":"King, N. P. et al. Accurate design of co-assembling multi-component protein nanomaterials. Nature 510, 103\u2013108 (2014).","journal-title":"Nature"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abf6840","article-title":"Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice","author":"Cohen AA","year":"2021","unstructured":"Cohen, A. A. et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice. Science 735\u2013741 (2021).","journal-title":"Science"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41590-018-0305-x","article-title":"Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses","volume":"20","author":"Kanekiyo M","year":"2019","unstructured":"Kanekiyo, M. et al. Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses. Nat. Immunol. 20, 362\u2013372 (2019).","journal-title":"Nat. Immunol."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e1012558","DOI":"10.1371\/journal.ppat.1012558","article-title":"Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes","volume":"20","author":"Brinkkemper M","year":"2024","unstructured":"Brinkkemper, M. et al. Mosaic and mixed HIV-1 glycoprotein nanoparticles elicit antibody responses to broadly neutralizing epitopes. PLOS Pathog. 20, e1012558 (2024).","journal-title":"PLOS Pathog."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"Boyoglu-Barnum S","year":"2021","unstructured":"Boyoglu-Barnum, S. et al. Quadrivalent influenza nanoparticle vaccines induce broad protection. Nature 592, 623\u2013628 (2021).","journal-title":"Nature"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"113553","DOI":"10.1016\/j.celrep.2023.113553","article-title":"Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses","volume":"42","author":"Dosey A","year":"2023","unstructured":"Dosey, A. et al. Combinatorial immune refocusing within the influenza hemagglutinin RBD improves cross-neutralizing antibody responses. Cell Rep. 42, 113553 (2023).","journal-title":"Cell Rep."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-024-00891-3","article-title":"Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge","volume":"9","author":"Pascha MN","year":"2024","unstructured":"Pascha, M. N. et al. Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge. Npj Vaccines 9, 1\u201314 (2024).","journal-title":"Npj Vaccines"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"e01652-21","DOI":"10.1128\/jvi.01652-21","article-title":"Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019","volume":"96","author":"Allen JD","year":"2022","unstructured":"Allen, J. D. & Ross, T. M. Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019. J. Virol. 96, e01652-21 (2022).","journal-title":"J. Virol."},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.00039","article-title":"Influenza virus neuraminidase structure and functions","volume":"10","author":"McAuley JL","year":"2019","unstructured":"McAuley, J. L., Gilbertson, B. P., Trifkovic, S., Brown, L. E. & McKimm-Breschkin, J. L. Influenza virus neuraminidase structure and functions. Front. Microbiol. 10, (2019).","journal-title":"Front. Microbiol."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/v16020316","article-title":"The Influenza A Virus Replication Cycle: A Comprehensive Review","volume":"16","author":"Carter T","year":"2024","unstructured":"Carter, T. & Iqbal, M. The Influenza A Virus Replication Cycle: A Comprehensive Review. Viruses 16, 316 (2024).","journal-title":"Viruses"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1128\/jvi.69.2.1099-1106.1995","article-title":"Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding","volume":"69","author":"Liu C","year":"1995","unstructured":"Liu, C., Eichelberger, M. C., Compans, R. W. & Air, G. M. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol. 69, 1099\u20131106 (1995).","journal-title":"J. Virol."},{"key":"ref38","author":"Krammer F","year":"2018","unstructured":"Krammer, F. et al. NAction! how can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9, (2018)."},{"key":"ref39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.786617","article-title":"A. M. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target","volume":"12","author":"Creytens S","year":"2021","unstructured":"Creytens, S., Pascha, M. N., Ballegeer, M., Saelens, X. & de Haan, C. A. M. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Front. Immunol. 12, (2021).","journal-title":"Front. Immunol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1093\/infdis\/jiz017","article-title":"Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection","volume":"219","author":"Eichelberger MC","year":"2019","unstructured":"Eichelberger, M. C. & Monto, A. S. Neuraminidase, the Forgotten Surface Antigen, Emerges as an Influenza Vaccine Target for Broadened Protection. J. Infect. Dis. 219, S75\u2013S80 (2019).","journal-title":"J. Infect. Dis."},{"key":"ref41","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/14760584.2024.2343689","article-title":"Anti-neuraminidase immunity in the combat against influenza","volume":"23","author":"Zhang X","year":"2024","unstructured":"Zhang, X. & Ross, T. M. Anti-neuraminidase immunity in the combat against influenza. Expert Rev. Vaccines 23, 474\u2013484 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"ref42","author":"Stadlbauer D","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase."},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06136-y","article-title":"A pan-influenza antibody inhibiting neuraminidase via receptor mimicry","author":"Momont C","year":"2023","unstructured":"Momont, C. et al. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature (2023) doi:10.1038\/s41586-023-06136-y.","journal-title":"Nature"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1038\/s41467-022-34521-0","article-title":"A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases","volume":"13","author":"Yasuhara A","year":"2022","unstructured":"Yasuhara, A. et al. A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases. Nat. Commun. 13, 6602\u20136602 (2022).","journal-title":"Nat. Commun."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0264-410X(97)00279-X","article-title":"Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response","volume":"16","author":"Johansson BE","year":"1998","unstructured":"Johansson, B. E., Matthews, J. T. & Kilbourne, E. D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16, 1009\u20131015 (1998).","journal-title":"Vaccine"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection","volume":"212","author":"Monto AS","year":"2015","unstructured":"Monto, A. S. et al. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J. Infect. Dis. 212, 1191\u20131199 (2015).","journal-title":"J. Infect. Dis."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1115485109\/-\/DCSupplemental","article-title":"Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin","author":"Zakeri B","unstructured":"Zakeri, B. et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. doi:10.1073\/pnas.1115485109\/-\/DCSupplemental."},{"key":"ref48","first-page":"325","volume-title":"Design and characterization of structured protein linkers with differing flexibilities","author":"Klein JS","year":"2014","unstructured":"Klein, J. S. et al. Design and characterization of structured protein linkers with differing flexibilities. in vol. 27 325\u2013330 (Oxford University Press, 2014)."},{"key":"ref49","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jmb.2009.04.078","article-title":"The Crystal Structure of Ferritin from Helicobacter pylori Reveals Unusual Conformational Changes for Iron Uptake","volume":"390","author":"Cho KJ","year":"2009","unstructured":"Cho, K. J. et al. The Crystal Structure of Ferritin from Helicobacter pylori Reveals Unusual Conformational Changes for Iron Uptake. J. Mol. Biol. 390, 83\u201398 (2009).","journal-title":"J. Mol. Biol."},{"key":"ref50","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.chom.2019.10.002","article-title":"Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies","volume":"26","author":"Zhu X","year":"2019","unstructured":"Zhu, X. et al. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Cell Host Microbe 26, 729\u2013738.e4 (2019).","journal-title":"Cell Host Microbe"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.immuni.2023.10.005","article-title":"Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase","volume":"56","author":"Lei R","year":"2023","unstructured":"Lei, R. et al. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Immunity 56, 2621\u20132634.e6 (2023).","journal-title":"Immunity"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.immuni.2024.02.003","article-title":"Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase","volume":"57","author":"Lederhofer J","year":"2024","unstructured":"Lederhofer, J. et al. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity 57, 574\u2013586.e7 (2024).","journal-title":"Immunity"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/bi962514+","article-title":"Refined Structure of an Intact IgG2a Monoclonal Antibody","volume":"36","author":"Harris LJ","year":"1997","unstructured":"Harris, L. J., Larson, S. B., Hasel, K. W. & McPherson, A. Refined Structure of an Intact IgG2a Monoclonal Antibody,. Biochemistry 36, 1581\u20131597 (1997).","journal-title":"Biochemistry"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.cell.2015.04.028","article-title":"Viral receptor-binding site antibodies with diverse germline origins","volume":"161","author":"Schmidt AG","year":"2015","unstructured":"Schmidt, A. G. et al. Viral receptor-binding site antibodies with diverse germline origins. Cell 161, 1026\u20131034 (2015).","journal-title":"Cell"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3791\/54573","article-title":"Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay","volume":"54573","author":"Gao J","year":"2016","unstructured":"Gao, J., Couzens, L. & Eichelberger, M. C. Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay. J. Vis. Exp. JoVE 54573 (2016) doi:10.3791\/54573.","journal-title":"J. Vis. Exp. JoVE"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.3791\/55570","article-title":"Fluorescence-based neuraminidase inhibition assay to assess the susceptibility of influenza viruses to the neuraminidase inhibitor class of antivirals","author":"Leang SK","year":"2017","unstructured":"Leang, S. K. & Hurt, A. C. Fluorescence-based neuraminidase inhibition assay to assess the susceptibility of influenza viruses to the neuraminidase inhibitor class of antivirals. J. Vis. Exp. (2017) doi:10.3791\/55570.","journal-title":"J. Vis. Exp."},{"key":"ref57","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3390\/vaccines9050431","article-title":"A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response","volume":"9","author":"Lain\u0161\u010dek D","year":"2021","unstructured":"Lain\u0161\u010dek, D. et al. A Nanoscaffolded Spike-RBD Vaccine Provides Protection against SARS-CoV-2 with Minimal Anti-Scaffold Response. Vaccines 9, 431 (2021).","journal-title":"Vaccines"},{"key":"ref58","first-page":"471","volume":"45","author":"Mesin L","year":"2016","unstructured":"Mesin, L., Ersching, J. & Victora, G. D. Germinal Center B Cell Dynamics. Immunity 45, 471\u2013482 (2016).","journal-title":"Germinal Center B Cell Dynamics. Immunity"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.cell.2019.03.016","article-title":"B Cell Responses: Cell Interaction Dynamics and Decisions","volume":"177","author":"Cyster JG","year":"2019","unstructured":"Cyster, J. G. & Allen, C. D. C. B Cell Responses: Cell Interaction Dynamics and Decisions. Cell 177, 524\u2013540 (2019).","journal-title":"Cell"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","article-title":"Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization","volume":"153","author":"Klein F","year":"2013","unstructured":"Klein, F. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153, 126\u2013138 (2013).","journal-title":"Cell"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"112044","DOI":"10.1016\/j.celrep.2023.112044","article-title":"Functional HIV-1\/HCV cross-reactive antibodies isolated from a chronically co-infected donor","volume":"42","author":"Pilewski KA","year":"2023","unstructured":"Pilewski, K. A. et al. Functional HIV-1\/HCV cross-reactive antibodies isolated from a chronically co-infected donor. Cell Rep. 42, 112044 (2023).","journal-title":"Cell Rep."},{"key":"ref62","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1093\/jimmun\/vkae056","article-title":"Rapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies","volume":"214","author":"Wang M","year":"2025","unstructured":"Wang, M. et al. Rapid clonal expansion and somatic hypermutation contribute to the fate of SARS-CoV-2 broadly neutralizing antibodies. J. Immunol. 214, 278\u2013289 (2025).","journal-title":"J. Immunol."},{"key":"ref63","doi-asserted-by":"crossref","first-page":"e01006-18","DOI":"10.1128\/JVI.01006-18","article-title":"Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype","volume":"92","author":"Walz L","year":"2018","unstructured":"Walz, L., Kays, S.-K., Zimmer, G. & von Messling, V. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype. J. Virol. 92, e01006-18 (2018).","journal-title":"J. Virol."},{"key":"ref64","doi-asserted-by":"crossref","first-page":"e02556","DOI":"10.1128\/mBio.02556-14","article-title":"Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice","volume":"6","author":"Wohlbold TJ","year":"2015","unstructured":"Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. mBio 6, e02556 (2015).","journal-title":"mBio"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"126574","DOI":"10.1016\/j.vaccine.2024.126574","article-title":"A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine","volume":"46","author":"Kaplan BS","year":"2025","unstructured":"Kaplan, B. S. et al. A neuraminidase-based inactivated influenza virus vaccine significantly reduced virus replication and pathology following homologous challenge in swine. Vaccine 46, 126574 (2025).","journal-title":"Vaccine"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"7864","DOI":"10.1038\/s41467-022-35586-7","article-title":"Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site","volume":"13","author":"Stadlbauer D","year":"2022","unstructured":"Stadlbauer, D. et al. Antibodies targeting the neuraminidase active site inhibit influenza H3N2 viruses with an S245N glycosylation site. Nat. Commun. 13, 7864 (2022).","journal-title":"Nat. Commun."},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05715-3","article-title":"Molecular fate-mapping of serum antibody responses to repeat immunization","author":"Schiepers A","year":"2023","unstructured":"Schiepers, A. et al. Molecular fate-mapping of serum antibody responses to repeat immunization. Nature (2023) doi:10.1038\/s41586-023-05715-3.","journal-title":"Nature"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"e1008109","DOI":"10.1371\/journal.ppat.1008109","article-title":"Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics","volume":"15","author":"Gostic KM","year":"2019","unstructured":"Gostic, K. M. et al. Childhood immune imprinting to influenza A shapes birth year-specific risk during seasonal H1N1 and H3N2 epidemics. PLoS Pathog. 15, e1008109 (2019).","journal-title":"PLoS Pathog."},{"key":"ref69","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00018-004-4513-1","article-title":"Type II restriction endonucleases: structure and mechanism","volume":"62","author":"Pingoud A","year":"2005","unstructured":"Pingoud, A., Fuxreiter, M., Pingoud, V. & Wende, W. Type II restriction endonucleases: structure and mechanism. Cell. Mol. Life Sci. CMLS 62, 685\u2013707 (2005).","journal-title":"Cell. Mol. Life Sci. CMLS"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1128\/CVI.00033-07","article-title":"Quality and Kinetics of the Antibody Response in Mice after Three Different Low-Dose Influenza Virus Vaccination Strategies","volume":"14","author":"Hauge S","year":"2007","unstructured":"Hauge, S., Madhun, A., Cox, R. J. & Haaheim, L. R. Quality and Kinetics of the Antibody Response in Mice after Three Different Low-Dose Influenza Virus Vaccination Strategies. Clin. Vaccine Immunol. CVI 14, 978\u2013983 (2007).","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00868\u2009\u2013\u200916","article-title":"An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity","volume":"91","author":"Zanin M","year":"2017","unstructured":"Zanin, M. et al. An Amino Acid in the Stalk Domain of N1 Neuraminidase Is Critical for Enzymatic Activity. J. Virol. 91, 10.1128\/jvi.00868\u2009\u2013\u200916 (2017).","journal-title":"J. Virol."},{"key":"ref72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/0264-410X(95)00157-V","article-title":"Recombinant neuraminidase vaccine protects against lethal influenza","volume":"14","author":"Deroo T","year":"1996","unstructured":"Deroo, T., Min Jou, W. & Fiers, W. Recombinant neuraminidase vaccine protects against lethal influenza. Vaccine 14, 561\u2013569 (1996).","journal-title":"Vaccine"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1107\/S2053230X18017892","article-title":"Structure of an influenza a virus n9 neuraminidase with a tetrabrachion-domain stalk","volume":"75","author":"Streltsov VA","year":"2019","unstructured":"Streltsov, V. A., Schmidta, P. M. & Breschkina, J. L. M. K. Structure of an influenza a virus n9 neuraminidase with a tetrabrachion-domain stalk. Acta Crystallogr. Sect. F Struct. Biol. Commun. 75, 89\u201397 (2019).","journal-title":"Acta Crystallogr. Sect. F Struct. Biol. Commun."},{"key":"ref74","doi-asserted-by":"crossref","first-page":"17027","DOI":"10.1073\/pnas.0403069101","article-title":"The VASP tetramerization domain is a right-handed coiled coil based on a 15-residue repeat","volume":"101","author":"K\u00fc K","year":"2004","unstructured":"K\u00fc, K. et al. The VASP tetramerization domain is a right-handed coiled coil based on a 15-residue repeat. PNAS 101, 17027\u201317032 (2004).","journal-title":"PNAS"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7530142\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7530142\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T16:55:25Z","timestamp":1772988925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7530142\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":74,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7530142\/v1","relation":{},"subject":[],"published":{"date-parts":[[2025,11,3]]},"subtype":"preprint"}}